Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab vs Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT04396860Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ipilimumab and nivolumab in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-free Survival up to 19.3 months and Overall Survival up to 19.3 months. Started Sep 2020; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT04396860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396860.